跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
查看斯高帕斯 (Scopus) 概要
張 志誠
成員
,
臺北醫學大學胸腔醫學研究中心
https://orcid.org/0000-0003-1183-2163
h-index
1911
引文
27
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2009
2025
每年研究成果
概覽
指紋
網路
專案
(3)
研究成果
(55)
類似的個人檔案
(6)
指紋
查看啟用 Chih-Cheng Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Adiponectin
40%
Ankylosing Spondylitis
20%
Anti-Inflammation
20%
Aromatic Hydrocarbon Receptor
85%
Beraprost
21%
Binding Protein
20%
Carboplatin
60%
Carnitine
46%
Chronic Inflammation
20%
Cohort Study
21%
Cyclic AMP Responsive Element Binding Protein
25%
Cyclooxygenase 2
21%
Endothelial Nitric Oxide Synthase
20%
Epidermal Growth Factor Receptor
85%
Erlotinib
25%
Heme
40%
Heme Oxygenase 1
21%
Histone Deacetylase 1
60%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
25%
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
24%
Inflammation
55%
Kidney Fibrosis
20%
Kidney Injury
27%
Liver Injury
20%
Lung Adenocarcinoma
42%
Lung Cancer
70%
Lung Tuberculosis
20%
Malignant Neoplasm
46%
Malignant Pleura Effusion
20%
Methylcholanthrene
100%
Mouse Model
22%
Nitric Oxide
23%
Non Small Cell Lung Cancer
46%
Nuclear Factor
29%
Oxygenase
40%
Perfluorooctanesulfonic Acid
40%
Peroxisome Proliferator Activated Receptor
87%
Peroxisome Proliferator Activated Receptor Alpha
40%
Pleura Effusion
47%
Pleurisy
20%
Pneumonia
40%
Polycyclic Aromatic Compound
20%
Polycyclic Aromatic Hydrocarbon
27%
Protein Binding
20%
Proton Pump Inhibitor
20%
Rat
34%
Receptor Agonist
25%
Simvastatin
44%
Tetramethylpyrazine
20%
Transcription Factor NFAT3
20%
Medicine and Dentistry
4 Iodo 2,5 Dimethoxyamphetamine
20%
Ankylosing Spondylitis
20%
Apoplexy
20%
Atmospheric Aerosol
25%
Biological Marker
25%
Biopsy Technique
20%
Bronchiectasis
20%
Cell Damage
21%
Community-Acquired Pneumonia
20%
COVID-19
20%
Early Diagnosis
20%
Endobronchial Ultrasonography
20%
Epidermal Growth Factor Receptor
40%
Germ Cell
23%
Glucose Metabolism
20%
Hospital Mortality
20%
Infection
20%
Inflammation
25%
Inflammatory Disorder
20%
Injection
27%
Intensive Care Unit
20%
Lung
55%
Lung Adenocarcinoma
20%
Lung Tuberculosis
20%
Malignant Neoplasm
23%
Malignant Pleural Effusion
20%
Mesenchymal Stem Cell
40%
Meta-Analysis
20%
Negative Pressure Ventilation
20%
Non Small Cell Lung Cancer
20%
Obstructive Sleep Apnea
20%
Odds Ratio
26%
Out of Hospital Cardiac Arrest
20%
Pleura Effusion
44%
Pleurisy
23%
Pneumonia
20%
Prediction Model
20%
Proton-Pump Inhibitor
20%
Quality of Life
20%
Sarcomatoid Carcinoma
20%
Sepsis
20%
Silo-Filler's Disease
20%
Sperm Motility
20%
Spontaneous Breathing Trial
20%
Testes
22%
Testis Torsion
40%
Tuberculosis
23%
Tyrosine-Kinase Inhibitor
20%
Ventilator Weaning
20%
Water-Electrolyte Imbalance
20%
Biochemistry, Genetics and Molecular Biology
2,5-Dimethoxy-4-iodoamphetamine
20%
Adipocyte
20%
Alkaline Phosphatase
11%
AMP-activated Protein Kinase
40%
Aryl Hydrocarbon Receptor
44%
Carnitine Palmitoyltransferase I
10%
Cell Cycle Arrest
20%
Cell Cycle Checkpoint
20%
Cell Cycle Protein
15%
Cell Migration
8%
Cell Motility
20%
Colon
10%
Comorbidity
10%
Deacetylation
20%
down Regulation
9%
E2F1
20%
Electrophoretic Mobility Shift Assay
7%
Epidermal Growth Factor Receptor
40%
Epigenetic Modification
10%
Folic Acid
20%
HDAC1
20%
Histone
20%
Homocysteine
20%
Immunoprecipitation
7%
Insulin-Like Growth Factor 1
20%
Lipolysis
20%
Macrophage
12%
Methionine Oxidation
20%
Molecular Mechanism
35%
Monocyte
7%
Myeloid
20%
P21
36%
Particulate Matter
20%
Peroxisome Proliferator-Activated Receptor Alpha
40%
phosphorylation
21%
Positive Feedback
20%
Programmed Cell Death
7%
Protein Kinase B
8%
Rat
20%
Receptor Agonists
24%
S100A9
40%
Simvastatin
9%
Standardized Incidence Ratio
20%
Statin
10%
Stem Cell
20%
Sulphur Dioxide
20%
Transcription Factor NFAT3
20%
Tyrosine Kinase Inhibitor
20%
Upregulation
12%
Western Blot
7%
